Meeting Banner
Abstract #2811

Clinical Utility of the PI-RADSv2.1 Combined with PSA Parmeters for Prostate Biopsy Indication

Yuchun Li1, Yunfu Zeng1, Siran Wang1, and Yi Zhu2
1The First People's Hospital of Yibin, Yibin, China, 2Philips Healthcare, Beijing, Beijing, China

Synopsis

Keywords: Prostate, Prostate, Biopsy Indication, PI-RADS, PSAD

Motivation: Prostate cancer diagnosis often relies on biopsies that carry risks, and traditional methods like PSA testing have limited accuracy.

Goal(s): Combine PI-RADS v2.1 scoring with PSAD to reduce unnecessary procedures without missing clinically significant prostate cancer (csPCa).

Approach: A retrospective analysis of 462 patients undergoing prostate biopsies; logistic regression identified independent risk factors; ROC curves evaluated diagnostic performance of the combined PI-RADS v2.1 score and PSAD.

Results: PI-RADS v2.1 score and PSAD are independent risk factors for csPCa. Combining them improved diagnostic accuracy (AUC = 0.964), allowing safe avoidance of biopsies in certain cases.

Impact: By integrating PI-RADS v2.1 scores with PSAD, this study offers a validated method to reduce unnecessary prostate biopsies by 40%, enhancing patient care and diagnostic precision for clinically significant prostate cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords